Almirall
ALM.MCApprovedA global pharmaceutical company focused on medical dermatology and skin health.
Market Cap
$2.8B
Founded
1943
Focus
Small Molecules
ALM.MC · Stock Price
USD 11.420.73 (-6.01%)
Historical price data
About
A global pharmaceutical company focused on medical dermatology and skin health.
Pipeline Snapshot
6666 drugs in pipeline, 21 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| lebrikizumab | Atopic Dermatitis | Approved |
| Tildrakizumab 100 mg Solution for Injection | Plaque Psoriasis | Approved |
| Pidotimod + Placebo | Recurrent Respiratory Tract Infections | Approved |
| Tiotropium + Aclidinium | Pulmonary Disease, Chronic Obstructive | Approved |
| dapsone gel | Acne Vulgaris | Approved |
Funding History
1IPOUndisclosedUndisclosedJul 3, 2007
FDA Approved Drugs
9KLISYRINDADec 14, 2020
SEYSARANDAOct 1, 2018
ACZONENDAFeb 24, 2016
Publications
20
Patents
5
Pipeline
66
FDA Approvals
9
Company Info
TypePublic
Founded1943
LocationBarcelona, Spain
StageApproved
Contact
SIMILAR COMPANIES
A4Cell
Pre-clinical · Barcelona
Ability Pharma
Phase 2 · Barcelona
Abyntek Biopharma
Pre-clinical · Derio
Acellera
Pre-clinical · Barcelona
BeCytes Biotechnologies
Pre-clinical · Barcelona
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile